News
-
Study shows glucocorticoids cut mortality in community acquired pneumonia in low-income settings
Anthony O. Etyang, MBChB, MMed, MSc, PhD, said recent data bolster the evidence that steroids may be useful for severe pneumonia in high-income settings as well.
-
Hypoxic burden emerges as a key cardiovascular risk marker in pediatric OSA
Investigator Olga Mediano, PhD, said hypoxic burden may more fully capture the physiological consequences of OSA by integrating the frequency, duration, and depth of oxygen desaturation events.
-
AI applications in pulmonary medicine: From training clinicians to transforming diagnostics and treatment
AI applications in health care are multiplying, and AI-focused research is gaining traction across specialties, including pulmonary, critical care, and sleep medicine.
-
Data show OSA is an independent, modifiable risk factor for cerebral microbleeds
The first prospective, longitudinal study of OSA and cerebral microbleeds (CMBs) found that moderate to severe OSA more than doubles the risk for microbleeds.
-
Targeting capillary refill time identified as superior resuscitation strategy
Yuri Matusov, MD, said recent findings mark a significant step toward an individualized approach for managing septic shock.
-
Trials suggest RSV vaccine reduces hospitalization for cardiorespiratory conditions in older adults
Data from studies in the United States and Denmark add to the growing evidence that respiratory syncytial virus (RSV) vaccination is effective in older adults.
-
Third trial supports sotatercept to treat PAH
Guidelines expert James R. Klinger, MD, FCCP, said that while the evidence of efficacy is clear, more research is needed to address questions regarding the optimal duration of therapy and the potential for disease progression if therapy is stopped.
-
Study demonstrates strong patient compliance with oral device for OSA
Evidence suggests that an oral device may be an effective alternative for patients who can’t access or tolerate CPAP therapy.
-
The climate cost of inhalers: What prescribers should know
Experts said clinicians must ensure patients have the therapies they need at affordable prices that, ideally, impose minimal amounts of environmental harm.
-
Phase 3 IMPALA-2 clinical trial shows inhaled molgramostim promising for autoimmune pulmonary alveolar proteinosis
An ongoing 96-week, open-label period of the trial is designed to shed light on the drug’s long-term safety and efficacy.
